-Prama Ghosh, Amity University Kolkata
Cancer Immunotherapy uses the immune system to eradicate cancer cells and prevent their spread in the body. It needs to be personalized because anticancer immune responses can be inhibited in various ways varying from person to person.
There are pharmaceutical and non – pharmaceutical approaches cancer immunotherapy which includes monoclonal antibodies (MAbs) and immune-gene therapy respectively. PD-1/PD-L1 drugs in combination with other immunotherapy drugs, as well as therapies, are also being explored.
Biomarkers and tumor organoids are significant for predicting response to immunotherapy in patients who are likely to respond in immunotherapy. Molecular diagnostics and Genomic profiling of tumor mutational burden (TMB) are significant for immunotherapy technologies. Advancement in cell therapy of malignancy is Chimeric antigen receptors (CAR)- T cell, which joins the antigen restricting site of a MAb with the signal enacting machinery of a T cell, liberating antigen recognition from significant histocompatibility complex (MHC) limitation. gene-editing tools, such as clustered regularly interspaced short palindromic repeats (CRISPR) have a promising application for removing alloreactivity and decreasing immunogenicity of third-party T cells, unlike vaccines which have a high failure rate in clinical trials.
In a nutshell, immuno-oncology, one of the most encouraging ways to deal with the principles of cancer fits in well with the standards of personalized medication.
Source: Personalized Immuno-oncology, Jain K, K, Med Princ Pract 2020..DOI: 10.1159/000511107
Well written…